From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Today, as part of our new advertising and public affairs initiative, GOBOLDLY™, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative immunotherapy treatments by America’s biopharmaceutical companies.
Cells is a rarely seen, front row seat to the destruction of a cancer cell by the body’s own immune system stimulated by new advancements in immuno-oncology. With this new style of targeted treatment, scientists have begun replacing chemotherapy with immunotherapy, dramatically improving the lives of patients and bringing us closer to the goal of one day rendering cancer obsolete.
Learn more about how America’s biopharmaceutical companies are working tirelessly to find new ways to fight cancer at GoBoldly.com and Innovation.org.
Robert Zirkelbach Robert Zirkelbach is Executive Vice President of Public Affairs at PhRMA. He joined PhRMA in 2014 after working for seven years representing the health insurance industry. He likes Saturday afternoon BBQs on his deck, traveling, trying new restaurants, and attempting to play golf. He’s an avid, somewhat obsessive, Iowa Hawkeye fan and is lucky to have a wife that loves watching college football on Saturday afternoons.
Topics: Cancer, New Era of Medicine, GoBoldly
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)